Alimta

Alimta is a brand name of pemetrexed, approved by the FDA in the following formulation(s):

ALIMTA (pemetrexed disodium - injectable; iv (infusion))

• 
  Manufacturer: LILLY
  
  Approval date: February 4, 2004
  
  Strength(s): EQ 500MG BASE/VIAL ^[RLD]


• 
  Manufacturer: LILLY
  
  Approval date: September 7, 2007
  
  Strength(s): EQ 100MG BASE/VIAL ^[RLD]

Has a generic version of Alimta been approved?

No. There is currently no therapeutically equivalent version of Alimta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Alimta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for treating gar-transformylase tumors in mammals and reducing mammalian toxicity
  Patent 5,217,974
  Issued: June 8, 1993
  Inventor(s): Grindey; Gerald B. & Shih; Chuan
  Assignee(s): Eli Lilly and Company
  Administration of a folate binding protein binding agent in conjunction with use of an antitumor agent which is an inhibitor of glycinamide ribonucleotide transformylase or other antifolate reduces the toxic effects of such agent and provides an enhanced therapeutic index.
  
  Patent expiration dates:
  
  
  • September 29, 2011
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  N-(pyrrolo(2,3-d)pyrimidin-3-ylacyl)-glutamic acid derivatives
  Patent 5,344,932
  Issued: September 6, 1994
  Inventor(s): Taylor; Edward C.
  Assignee(s): Trustees of Princeton University
  N-(Acyl)glutamic acid derivatives in which the acyl group is substituted with 4-hydroxypyrrolo[2,3-d]-pyrimidin-3-yl group are antineoplastic agents. A typical embodiment is N-[4-(2-{4-hydroxy-6-aminopyrrolo-[2,3-d]pyrimidin-3-yl}ethyl)benzoyl]-L-g lutamic acid.
  
  Patent expiration dates:
  
  
  • July 24, 2016
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • January 24, 2017
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Antifolate combination therapies
  Patent 7,772,209
  Issued: August 10, 2010
  Inventor(s): Niyikiza; Clet
  Assignee(s): Eli Lilly and Company
  A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent.
  
  Patent expiration dates:
  
  
  • November 24, 2021
    
    ✓ 
    Patent use: PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRAION
  
  
  
  • May 24, 2022
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • February 4, 2011 - ORPHAN DRUG EXCLUSIVITY
  
  
  • August 4, 2011 - PEDIATRIC EXCLUSIVITY
  
  
  • September 26, 2011 - NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQAUMOUS NON-SMALL CELL LUNG CANCER
  
  
  • March 26, 2012 - PEDIATRIC EXCLUSIVITY
  
  
  • July 2, 2012 - MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY
  
  
  • January 2, 2013 - PEDIATRIC EXCLUSIVITY
  
  
  • March 17, 2014 - REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
  
  
  • September 17, 2014 - PEDIATRIC EXCLUSIVITY
  
  

See also...

• Alimta Consumer Information (Drugs.com)
• Alimta Consumer Information (Wolters Kluwer)
• Alimta Consumer Information (Cerner Multum)
• Alimta Advanced Consumer Information (Micromedex)
• Alimta AHFS DI Monographs (ASHP)
• Pemetrexed Consumer Information (Wolters Kluwer)
• Pemetrexed Consumer Information (Cerner Multum)
• Pemetrexed Intravenous Advanced Consumer Information (Micromedex)
• Pemetrexed Disodium AHFS DI Monographs (ASHP)